Lochhead, Pamela, Tucker, Julie Ann orcid.org/0000-0002-6119-676X, Tatum, Natalie et al. (8 more authors) (2020) Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. Nature Communications. 1383. ISSN 2041-1723
Abstract
The dual protein kinase-transcription factor, ERK5, is an emerging drug target in cancer and inflammation, and small-molecule ERK5 kinase inhibitors have been developed. However, selective ERK5 kinase inhibitors fail to recapitulate ERK5 genetic ablation phenotypes, suggesting kinase-independent functions for ERK5. Here we show that ERK5 kinase inhibitors cause paradoxical activation of ERK5 transcriptional activity mediated through its unique C-terminal transcriptional activation domain (TAD). Using the ERK5 kinase inhibitor, Compound 26 (ERK5-IN-1), as a paradigm, we have developed kinase-active, drug-resistant mutants of ERK5. With these mutants, we show that induction of ERK5 transcriptional activity requires direct binding of the inhibitor to the kinase domain. This in turn promotes conformational changes in the kinase domain that result in nuclear translocation of ERK5 and stimulation of gene transcription. This shows that both the ERK5 kinase and TAD must be considered when assessing the role of ERK5 and the effectiveness of anti-ERK5 therapeutics.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © The Author(s) 2020 |
Dates: |
|
Institution: | The University of York |
Academic Units: | The University of York > Faculty of Sciences (York) > Biology (York) |
Depositing User: | Pure (York) |
Date Deposited: | 18 Mar 2020 15:30 |
Last Modified: | 22 Jan 2025 00:14 |
Published Version: | https://doi.org/10.1038/s41467-020-15031-3 |
Status: | Published |
Refereed: | Yes |
Identification Number: | 10.1038/s41467-020-15031-3 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:158535 |
Download
Filename: s41467_020_15031_3.pdf
Description: Paradoxical activation of the protein kinasetranscription factor ERK5 by ERK5 kinase inhibitors
Licence: CC-BY 2.5